Bradford J. Shafer's most recent trade in Theravance Biopharma Inc was a trade of 4,307 Ordinary Shares done at an average price of $14.0 . Disclosure was reported to the exchange on Aug. 20, 2021.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Theravance Biopharma Inc | Bradford J. Shafer | EVP, Gen. Counsel, Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.05 per share. | 20 Aug 2021 | 4,307 | 277,831 (0%) | 0% | 14.0 | 60,513 | Ordinary Shares |
Theravance Biopharma Inc | Bradford J. Shafer | EVP, Gen. Counsel, Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.80 per share. | 20 May 2021 | 4,310 | 282,138 (0%) | 0% | 17.8 | 76,718 | Ordinary Shares |
Theravance Biopharma Inc | Bradford J. Shafer | EVP, Gen. Counsel, Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.79 per share. | 20 Feb 2021 | 31,869 | 285,047 (0%) | 0% | 18.8 | 598,819 | Ordinary Shares |
Theravance Biopharma Inc | Bradford J. Shafer | EVP, Gen. Counsel, Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 65,000 | 316,916 (0%) | 0% | 0 | Ordinary Shares | |
Theravance Biopharma Inc | Bradford J. Shafer | EVP, Gen. Counsel, Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.21 per share. | 20 Nov 2020 | 4,807 | 251,916 (0%) | 0% | 17.2 | 82,728 | Ordinary Shares |
Theravance Biopharma Inc | Bradford J. Shafer | EVP, Gen. Counsel, Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.22 per share. | 20 Aug 2020 | 4,804 | 256,723 (0%) | 0% | 18.2 | 87,529 | Ordinary Shares |